Trial Profile
A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Adult Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Indoximod (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Indigo301
- Sponsors Lumos Pharma; NewLink Genetics Corporation
- 03 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 17 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2018 According to a NewLink Genetics Corporation media release, results form this trial are being presented today and tomorrow at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington D.C.